Rallybio share price logo

Rallybio

NASDAQ: RLYB

$17.08

+0.18

(+1.07%)

as on

Rallybio Stock Performance

as on October 7, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $16.85
    $16.87
    downward going graph

    1.35%

    Downside

    -1.23%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $3.67
    $17.57
    downward going graph

    78.51%

    Downside

    2.89%

    Upside

    downward going graph

Rallybio share price movements today

Previous Close
$16.90
Open
$16.87
Volume
28.4K
Market Cap
$89.8M
Day's Low - High
$16.85 - $16.87
52 Week Low - High
$3.67 - $17.57

Rallybio Historical Returns

1 Month Return
+ 0.92 %
3 Month Return
+ 9 %
1 Year Return
+ 281.25 %
3 Year Return
-40.69 %
5 Year Return
-88.73 %

Rallybio Stock Fundamentals & Key Indicators

Check Rallybio market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$89.8M

EPS (TTM)

7.93

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

2.13

Industry PE ratio

-2.28

PEG Ratio

0.00

EBITDA

27.0M

Revenue (TTM)

646.0K

Profit Margin

-1107.59%

Return On Equity TTM

68.56%

Rallybio vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Rallybio with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Buy$89.8M-88.73%2.13-1107.59%0.00%
StrongBuy$44.5B617.67%-23.440.00%0.00%
Neutral$81.1B-39.40%-25.46-12.57%0.00%
StrongBuy$127.9B178.32%29.1486.04%0.00%
Buy$75.7B33.82%17.3584.86%0.51%

Stock Returns calculator for Rallybio Stock including INR - Dollar returns

The Rallybio stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Rallybio investment value today

Current value as on today

₹4,14,334

Returns

₹3,14,334

(+314.33%)

Returns from Rallybio Stock

₹2,81,250 (+281.25%)

Dollar Impact

₹33,084 (+33.08%)

Analyst Recommendation on Rallybio Stock

Based on 12 analysts

BUY

91.67%

Buy

8.33%

Hold

0.00%

Sell

Based on 12 analysts, 91.67% of analysts recommend a 'BUY' rating for Rallybio. Average target price of $8

Rallybio Share Price Target

Get share price movements and forecasts by analysts on Rallybio.

What analysts predicted

-113.5%DOWNSIDE

Target Price

$8

Current Price

$17.08

Analyzed by

12 Analysts

Target

$8.00

Rallybio target price $8, a slight downside of -113.5% compared to current price of $17.08. According to 12 analysts rating.

Indian Investors' Interest in Rallybio Stock

Search interest for Rallybio Stock has decreased by -27% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-27% versus previous 30 day period

Rallybio Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
-
0
0
0
0
0
0
0
0
-
Gross Profit
0
0
-7
0
-5
-5
-3
-3
0
-
Operating Income
-19
-17
-12
-11
-9
-10
-6
-6
-4
-5
EBITDA
-19
-17
-12
-11
-9
-10
-6
-6
-4
44
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-19
-16
-11
-11
-9
-9
16
-5
-8
44
Income Tax Expense
-
-
-
-
-
-
-
-
-
1
Net Income
-19
-16
-11
-11
-9
-9
16
-5
-8
43
Net Profit Margin
0.00%
88.63%
100.00%
21.05%
-2600.47%
-2765.09%
-1854.25%
-1546.40%
98.58%
0.00%

Rallybio Annual Profit & Loss

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
-
-
-
0
0
Gross Profit
0
0
0
-
0
-38
0
Operating Income
-17
-25
-45
-67
-78
-60
-28
EBITDA
-17
-25
-45
-67
-78
-60
-27
Interest Expense
0
0
0
-
-
-
-
Depreciation
0
0
0
0
0
0
0
Income Before Tax
-17
-26
-47
-66
-74
-57
-8
Income Tax Expense
-
0
-
-
-
-
-
Net Income
-17
-26
-47
-66
-74
-57
-8
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
100.00%
89.28%

Rallybio Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-19
-16
-11
-11
-9
-9
16
-5
-8
43
Operating Cash Flow
-15
-10
-13
-9
-10
-8
-6
-4
-7
45
Investing Cash Flow
10
2
22
-1
11
3
29
3
17
5
Financing Cash Flow
-
5
0
0
-
0
-
0
0
0
Change in Cash
-5
-2
8
-11
0
-5
22
0
9
51

Rallybio Annual Cash Flow

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-17
-26
-47
-66
-74
-57
-8
Operating Cash Flow
-15
-22
-45
-57
-60
-49
-29
Investing Cash Flow
0
-2
-2
-112
27
33
47
Financing Cash Flow
31
144
82
51
0
5
0
Change in Cash
16
120
35
-118
-32
-10
17

Global Institutional Holdings in Rallybio

Check out the Institutions with significant holdings in Rallybio.

Funds
Holdings
Andreas Halvorsen
9.87%
Vanguard
3.15%
VANGUARD INDEX FUNDS
2.11%
TIAA-CREF Funds
0.79%
Fidelity Concord Street Trust
0.49%

Insights on Rallybio

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 6 months, RLYB stock has moved up by 112.2%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 80.5% return, outperforming this stock by 121.2%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 585.7% return, outperforming this stock by 304.5%

About Rallybio

Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with RLYB211, is aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company's pipeline also includes RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for addressing ophthalmic conditions driven by complement system activity. Furthermore, RLYB116, an inhibitor designed to target complement component 5 (C5) for various complement dysregulation disorders, has successfully completed its Phase 1 trial. Another preclinical antibody, RLYB332, is under investigation for treating severe anemia characterized by ineffective erythropoiesis and iron overload. Rallybio has established strategic collaborations to further its development efforts. It maintains an alliance with AbCellera for the identification, development, and commercialization of novel antibody-based therapeutics in rare diseases. Additionally, the firm partners with Exscientia on the creation of small molecule therapeutics for rare diseases, and with Johnson & Johnson to deliver therapeutic options to expectant mothers at risk of fetal and neonatal alloimmune thrombocytopenia. Established in 2018, Rallybio Corporation is headquartered in New Haven, Connecticut.
OrganisationRallybio
Headquarters234 Church Street, New Haven, CT, 06510, US
IndustryBiotechnology
CEOStephen Uden

Key Management of Rallybio

Name

Title

Dr. Martin W. MacKay Ph.D.

Co-Founder & Chairman

Dr. Stephen Uden M.D., MBBS

Co-Founder, President, CEO & Director

FAQs

What is Rallybio share price today?

Rallybio share price today is $17.08 as on at the close of the market. Rallybio share today touched a day high of $16.87 and a low of $16.85.

What is the 52 week high and 52 week low for Rallybio share?

Rallybio share touched a 52 week high of $17.57 on and a 52 week low of $3.67 on . Rallybio stock price today i.e. is closed at $17.08,which is 2.81% down from its 52 week high and 365.38% up from its 52 week low.

What is Rallybio's market capitalisation today?

Rallybio market capitalisation is $0.00T as on .

How to invest in Rallybio Stock (RLYB) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Rallybio on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Rallybio Stock (RLYB) from India?

Indian investors can start investing in Rallybio (RLYB) shares with as little as ₹96.419998168945 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹964.20 in Rallybio stock (as per the Rupee-Dollar exchange rate as on ). Based on Rallybio share’s latest price of $17.08 as on October 7, 2026 at 8:45 am IST, you will get 0.5855 shares of Rallybio. Learn more about fractional shares .

What are the returns that Rallybio has given to Indian investors in the last 5 years?

Rallybio stock has given -88.73% share price returns and 28.78% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?